Perrigo Company ( (PRGO) ) has released its Q3 earnings. Here is a breakdown of the information Perrigo Company presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Perrigo Company plc is a leading provider of consumer health products, primarily operating in the over-the-counter (OTC) self-care market, with a significant presence in North America and Europe. The company focuses on offering accessible health solutions across various price points and categories, including store brand private label offerings and leading brands like Opill and Mederma.
In its third quarter of 2025, Perrigo reported a decrease in net sales by 4.1% year-over-year, amounting to $1.04 billion. Despite facing challenges in the marketplace, the company achieved growth in earnings per share (EPS) and expanded its gross and operating margins. The company also announced strategic reviews of its Infant Formula and Oral Care businesses, alongside the planned sale of its Dermacosmetics business.
Key financial metrics revealed a reported operating income of $73 million, a decrease from $80 million in the prior year, while adjusted operating income stood at $173 million, down by 4.9%. The company’s adjusted EPS was $0.80, slightly down from $0.81 in the previous year. Perrigo’s Consumer Self-Care Americas segment saw a 3.8% decline in net sales, while the Consumer Self-Care International segment experienced a 4.5% decrease, both impacted by soft OTC market consumption and strategic business reviews.
Looking forward, Perrigo has updated its full-year 2025 outlook, anticipating net sales growth to decline by 2.5% to 3.0% and adjusted EPS growth to range between 5% and 9%. The company remains focused on managing through industry dynamics and market trends by leveraging share gains and strategic initiatives to support its growth expectations.
Overall, Perrigo continues to navigate a challenging market environment with a strategic focus on portfolio evaluation and operational efficiency, aiming to maintain its position as a leader in the OTC self-care market.